Brentuximab vedotin is used in relapsed Hodgkin lymphoma and anaplastic large cell lymphoma. Its antitumour action depends on which pair of target antigen and attached cytotoxic payload?
- A CD20 conjugated to iodine-131
- B CD33 conjugated to calicheamicin
- C CD30 conjugated to monomethyl auristatin E ✓
- D CD22 conjugated to ozogamicin-derived toxin
Correct answer: C. CD30 conjugated to monomethyl auristatin E
Explanation
Brentuximab vedotin is an antibody-drug conjugate linking an anti-CD30 antibody to monomethyl auristatin E, a microtubule-disrupting agent released after internalisation, causing G2/M arrest and apoptosis. CD30 is strongly expressed on Reed-Sternberg cells and anaplastic large cell lymphoma. Gemtuzumab ozogamicin pairs CD33 with calicheamicin in acute myeloid leukaemia, and ibritumomab tiuxetan delivers yttrium-90 to CD20, so options A, B and D describe different real drugs with mismatched pairings.
Reference: Katzung Basic and Clinical Pharmacology, 15th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.